Literature DB >> 16816556

Tuberculosis after HAART initiation in HIV-positive patients from five countries with a high tuberculosis burden.

Maryline M B Bonnet1, Loretxu L P Pinoges, Francis F V Varaine, Barbara B O Oberhauser, Daniel D O O'Brien, Yared Y K Kebede, Cathy C H Hewison, Rony R Z Zachariah, Laurent L F Ferradini.   

Abstract

BACKGROUND: HAART reduces tuberculosis (TB) incidence in people living with HIV/AIDS but those starting HAART may develop active TB or subclinical TB may become apparent in the immune reconstitution inflammatory syndrome.
OBJECTIVE: To measure the incidence rate of notified TB in people receiving HAART in five HIV programmes occurring in low-resource countries with a high TB/HIV burden.
METHODS: A retrospective review in five Médecins Sans Frontières programmes (Cambodia, Thailand, Kenya, Malawi and Cameroon) allowed incidence rates of notified TB to be calculated based on follow-up time after HAART initiation. RESULT: Among 3151 patients analysed, 90% had a CD4 cell count of < 200 cells/mul. Median follow-up time ranged from 3.7 months in Thailand or Kenya to 11.1 months in Cambodia. Incidence rates were 7.6, 10.4, 17.6, 14.3 and 4.8/100 person-years for pulmonary TB and 12.7, 4.3, 6.9, 2.1 and 0/100 person-years for extra-pulmonary TB in the programmes in Cambodia, Thailand, Kenya, Malawi and Cameroon, respectively. Overall, 62.3% of pulmonary TB and 54.9% of extra-pulmonary TB were diagnosed within 3 months after HAART initiation.
CONCLUSION: High incidence rates of notified TB under HAART in programmes held in poor-resource countries were observed; these were likely to include both undiagnosed prevalent TB at HAART initiation and subclinical TB developing during the immune reconstitution inflammatory syndrome. This raises operational issues concerning TB diagnosis and treatment of TB/HIV-coinfected patients and prompts for urgent TB and HIV care integration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16816556     DOI: 10.1097/01.aids.0000232235.26630.ee

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  32 in total

1.  Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies.

Authors:  Annelies Van Rie; Daniel Westreich; Ian Sanne
Journal:  J Acquir Immune Defic Syndr       Date:  2011-04       Impact factor: 3.731

2.  Tuberculosis risk before and after highly active antiretroviral therapy initiation: does HAART increase the short-term TB risk in a low incidence TB setting?

Authors:  April C Pettit; Cathy A Jenkins; Samuel E Stinnette; Peter F Rebeiro; Robert B Blackwell; Stephen P Raffanti; Bryan E Shepherd; Timothy R Sterling
Journal:  J Acquir Immune Defic Syndr       Date:  2011-08-01       Impact factor: 3.731

3.  Prevalence, characteristics, management, and outcome of pulmonary tuberculosis in HIV-infected children in the TREAT Asia pediatric HIV Observational Database (TApHOD).

Authors:  Tavitiya Sudjaritruk; Alan Maleesatharn; Wasana Prasitsuebsai; Siew Moy Fong; Ngoc Oanh Le; Thanh Thuy Thi Le; Pagakrong Lumbiganon; Nagalingeswaran Kumarasamy; Nia Kurniati; Rawiwan Hansudewechakul; Nik Khairulddin Nik Yusoff; Kamarul Azahar Mohd Razali; Azar Kariminia; Annette H Sohn; Virat Sirisanthana
Journal:  AIDS Patient Care STDS       Date:  2013-11-09       Impact factor: 5.078

4.  Etiology of suspected pneumonia in adults admitted to a high-dependency unit in Blantyre, Malawi.

Authors:  Thomas K Hartung; Daniel Chimbayo; Joep J G van Oosterhout; Tarsizio Chikaonda; Gerard J J van Doornum; Eric C J Claas; Willem J G Melchers; Malcolm E Molyneux; Ed E Zijlstra
Journal:  Am J Trop Med Hyg       Date:  2011-07       Impact factor: 2.345

5.  Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy.

Authors:  Stephen D Lawn; Katharina Kranzer; David J Edwards; Matthew McNally; Linda-Gail Bekker; Robin Wood
Journal:  AIDS       Date:  2010-06-01       Impact factor: 4.177

6.  Immune Reconstitution Inflammatory Syndrome in HIV-Infected Immigrants.

Authors:  María Pérez-Rueda; Michele Hernández-Cabrera; Adela Francés-Urmeneta; Alfonso Angel-Moreno; Elena Pisos-Álamo; Nieves Jaén-Sánchez; Cristina Carranza-Rodríguez; Jose-Luis Pérez-Arellano
Journal:  Am J Trop Med Hyg       Date:  2017-08-18       Impact factor: 2.345

7.  Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa.

Authors:  Sabine M Hermans; Agnes N Kiragga; Petra Schaefer; Andrew Kambugu; Andy I M Hoepelman; Yukari C Manabe
Journal:  PLoS One       Date:  2010-05-07       Impact factor: 3.240

8.  Short and Long-Term Incidence of Tuberculosis and CD4-Cell Count Dynamic on HAART in Senegal.

Authors:  Jean-François Etard; Assane Diouf; Pierre De Beaudrap; Koivugui Akoi; Ndèye Fatou Ngom-Guèye; Ibrahima Ndiaye; René Ecochard; Papa Salif Sow; Delaporte Eric
Journal:  Open AIDS J       Date:  2009-12-31

9.  Tuberculosis after one year of combination antiretroviral therapy in Nigeria: a retrospective cohort study.

Authors:  Maxwell O Akanbi; Chad J Achenbach; Joe Feinglass; Babafemi Taiwo; Adamu Onu; Mai T Pho; Oche Agbaji; Phyllis Kanki; Robert L Murphy
Journal:  AIDS Res Hum Retroviruses       Date:  2013-02-25       Impact factor: 2.205

Review 10.  Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings.

Authors:  Stephen D Lawn; Katharina Kranzer; Robin Wood
Journal:  Clin Chest Med       Date:  2009-12       Impact factor: 2.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.